The CANABID-LD study is looking at how a medication called cannabidiol (brand name Epidyolex) affects adults who have certain rare and severe epilepsy conditions (Dravet syndrome, Lennox-Gastaut syndrome and tuberous sclerosis complex). People with these conditions often have intellectual disabilities and have difficulties with challenging behaviours. Researchers want to understand whether this medication helps reduce challenging behaviours, seizure frequency and improves quality of life for these individuals.
This study is not a clinical trial but an observational one, which means researchers will monitor and collect data from people who are scheduled to start the medication as part of their usual care.
The study is being led by
Professor Rohit Shankar
from the University of Plymouth, supported by the
Peninsula Clinical Trials Unit (PenCTU)
, and funded by Jazz Pharmaceuticals. Around 60 participants will be recruited from about 10 different NHS locations in England and Wales.
If you would like to learn more about the study, please get in touch with us at canabid.penctu@plymouth.ac.uk
The CANABID-LD Trial
Jazz Pharmaceuticals
Faculty of Health
UK Clinical Research Collaboration